Mindy and Ryan are joined by friends and colleagues, Karen Baldry & Chris Savage to debate why new medicines matter. With novel therapies addressing complex disease states that come with significant price points, the panel discusses why the launch of a new product is critical for life science organizations. The panel discusses what it means that an increasing number of launches fall into specialty markets and how launch practices are shifting to reflect new dynamics and complexity.